Systematic approach to outcome assessment from coded electronic healthcare records in the DaRe2THINK NHS-embedded randomized trial
Xiaoxia Wang, Alastair Mobley, Otilia Țica, Kelvin Okoth, Rebecca Ghosh, Puja Myles, Tim Williams, Sandra Haynes, Krishnarajah Nirantharakumar, David Shukla, Dipak Kotecha, Susan Beatty, Samir Mehta, Sophie Breeze, Karen Z. Lancaster, Stuart Fordyce, Naomi E. Allen, Melanie Calvert, Alastair K. Denniston, George Gkoutos, Sahan Jayawardana, Simon Ball, Colin Baigent, Peter Brocklehurst, Will Lester, Richard J. McManus, Stefano Seri, Janet Valentine, A. John Camm, Sandra Haynes, Dame Julie Moore, Amy Rogers, Mary Stanbury, Marcus Flather, Suzy Walker, Duolao Wang
Abstract
Aims: Improving the efficiency of clinical trials is key to their continued importance in directing evidence-based patient care. Digital innovations, in particular the use of electronic healthcare records (EHRs), allow for large-scale screening and follow up of participants. However, it is critical these developments are accompanied by robust and transparent methods that can support high-quality and high clinical value research. Methods and results: The DaRe2THINK trial includes a series of novel processes, including nationwide pseudonymized pre screening of the primary-care EHR across England, digital enrolment, remote e-consent, and 'no-visit' follow up by linking all primary- and secondary-care health data with patient-reported outcomes. DaRe2THINK is a pragmatic, healthcare-embedded randomized trial testing whether earlier use of direct oral anticoagulants in patients with prior or current atrial fibrillation can prevent thromboembolic events and cognitive decline (www.birmingham.ac.uk/dare2think). This study outlines the systematic approach and methodology employed to define patient information and outcome events. This includes transparency on all medical code lists and phenotypes used in the trial across a variety of national data sources, including Clinical Practice Research Datalink Aurum (primary care), Hospital Episode Statistics (secondary care), and the Office for National Statistics (mortality). Conclusion: Co-designed by a patient and public involvement team, DaRe2THINK presents an opportunity to transform the approach to randomized trials in the setting of routine healthcare, providing high-quality evidence generation in populations representative of the community at risk.